PRX302
-
Protox Inks Agreement with Kissei for Commercialization of Prostate Disease Treatment
Protox Therapeutics has entered into an exclusive US$75 million license agreement with Kissei Pharmaceutical for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for Benign prostatic hyperplasia (BPH), prostate ca…
PRX302 | 14 May 2010
